China NMPA approves Hutchmed's Orpathys in combo with Tagrisso to treat lung cancer patients with MET amplification ...
Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National …